{"transactions":[{"id":1203537,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":81896,"kind":"person","name":"Hoffmann Bernhard","position":1,"cik":"0001830354","reported_name":"Hoffmann Bernhard","relationship":{"officer":true,"officer_title":"SVP of Corp. Dev."}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-18T00:49:52.000Z","date":"2025-03-13","kind":"grant","planned":false,"acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest with respect to 25% on March 13, 2026, with the remaining shares vesting quarterly in 12 equal installments thereafter at the end of each quarter, subject to the Reporting Person's continuing service."}],"balance_after":29500,"derivative":{"exercise_price":0.93,"expiration_date":"2035-03-12","underlying":"Common Stock","underlying_shares":29500},"source":{"system":"sec-edgar","filing":"0000905148-25-000937","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000090514825000937/form4.xml","form_type":"4"}},{"id":1203536,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":81896,"kind":"person","name":"Hoffmann Bernhard","position":1,"cik":"0001830354","reported_name":"Hoffmann Bernhard","relationship":{"officer":true,"officer_title":"SVP of Corp. Dev."}}],"security":"Common Stock","published_at":"2025-03-18T00:49:52.000Z","date":"2025-03-13","kind":"grant","planned":false,"acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units which vest in four equal installments on the first, second, third and fourth anniversary of the grant date of March 13, 2025, subject to the Reporting Person's continuing service."}],"balance_after":185446,"source":{"system":"sec-edgar","filing":"0000905148-25-000937","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000090514825000937/form4.xml","form_type":"4"}},{"id":1280165,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":81896,"kind":"person","name":"Hoffmann Bernhard","position":1,"cik":"0001830354","reported_name":"Hoffmann Bernhard","relationship":{"officer":true,"officer_title":"SVP of Corp. Dev."}}],"security":"Common Stock","published_at":"2025-02-06T21:35:31.000Z","date":"2025-02-04","kind":"tax_withholding","planned":false,"acquired":false,"shares":6751,"price":1.14,"value":7696.14,"ownership":{"direct":true},"balance_after":155946,"source":{"system":"sec-edgar","filing":"0000905148-25-000401","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000090514825000401/form4.xml","form_type":"4"}},{"id":1674073,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":81896,"kind":"person","name":"Hoffmann Bernhard","position":1,"cik":"0001830354","reported_name":"Hoffmann Bernhard","relationship":{"officer":true,"officer_title":"SVP of Corp. Dev."}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-22T23:01:13.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest with respect to 7,500 shares on January 18, 2025, with the balance vesting quarterly in twelve equal installments thereafter at the end of each quarter."}],"balance_after":30000,"derivative":{"exercise_price":2.77,"expiration_date":"2034-01-17","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001140361-24-003192","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036124003192/form4.xml","form_type":"4"}},{"id":1674072,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":81896,"kind":"person","name":"Hoffmann Bernhard","position":1,"cik":"0001830354","reported_name":"Hoffmann Bernhard","relationship":{"officer":true,"officer_title":"SVP of Corp. Dev."}}],"security":"Common Stock","published_at":"2024-01-22T23:01:13.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units which vest in four equal installments on the first, second, third and fourth anniversary of the grant date of January 18, 2024."}],"balance_after":162697,"source":{"system":"sec-edgar","filing":"0001140361-24-003192","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036124003192/form4.xml","form_type":"4"}},{"id":1679863,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":81896,"kind":"person","name":"Hoffmann Bernhard","position":1,"cik":"0001830354","reported_name":"Hoffmann Bernhard","relationship":{"officer":true,"officer_title":"SVP of Corp. Dev."}}],"security":"Common Stock","published_at":"2024-01-12T21:17:14.000Z","date":"2024-01-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":4031,"price":3.265,"value":13161.215,"ownership":{"direct":true},"balance_after":142697,"source":{"system":"sec-edgar","filing":"0001140361-24-002126","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036124002126/form4.xml","form_type":"4"}},{"id":2055513,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":81896,"kind":"person","name":"Hoffmann Bernhard","position":1,"cik":"0001830354","reported_name":"Hoffmann Bernhard","relationship":{"officer":true,"officer_title":"SVP of Corp. Dev. & Ops & Sec."}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-01-12T22:33:57.000Z","date":"2023-01-10","kind":"grant","acquired":true,"shares":69912,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest with respect to 17,478 shares on January 10, 2024, with the balance vesting quarterly in twelve equal installments thereafter."}],"balance_after":69912,"derivative":{"exercise_price":3.5,"expiration_date":"2033-01-09","underlying":"Common Stock","underlying_shares":69912},"source":{"system":"sec-edgar","filing":"0001140361-23-001513","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123001513/form4.xml","form_type":"4"}},{"id":2055512,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":81896,"kind":"person","name":"Hoffmann Bernhard","position":1,"cik":"0001830354","reported_name":"Hoffmann Bernhard","relationship":{"officer":true,"officer_title":"SVP of Corp. Dev. & Ops & Sec."}}],"security":"Common Stock","published_at":"2023-01-12T22:33:57.000Z","date":"2023-01-10","kind":"grant","acquired":true,"shares":46608,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of  restricted stock units which vest in four equal installments on the first, second, third and fourth anniversary of the grant date of January 10, 2023."}],"balance_after":146728,"source":{"system":"sec-edgar","filing":"0001140361-23-001513","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123001513/form4.xml","form_type":"4"}},{"id":2419032,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":81896,"kind":"person","name":"Hoffmann Bernhard","position":1,"cik":"0001830354","reported_name":"Hoffmann Bernhard","relationship":{"officer":true,"officer_title":"VP of Corp. Dev. & Ops & Sec."}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-01T21:29:46.000Z","date":"2022-01-28","kind":"grant","acquired":true,"shares":42500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest with respect to 10,625 shares on January 28, 2023, and then with respect to 885 shares on the last day of each month from February 2023 through December 2025 and with respect to 900 shares at the end of January 2026."}],"balance_after":42500,"derivative":{"exercise_price":2.9,"expiration_date":"2032-01-27","underlying":"Common Stock","underlying_shares":42500},"source":{"system":"sec-edgar","filing":"0001140361-22-003497","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036122003497/form4.xml","form_type":"4"}},{"id":2980856,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":81896,"kind":"person","name":"Hoffmann Bernhard","position":1,"cik":"0001830354","reported_name":"Hoffmann Bernhard","relationship":{"officer":true,"officer_title":"VP of Corp. Dev. & Ops & Sec."}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-11-13T21:57:40.000Z","date":"2020-11-11","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"416 shares vest each month-end from November 2020 through September 2024.  The balance vests in October 2024."}],"balance_after":20000,"derivative":{"exercise_price":4.05,"expiration_date":"2030-11-11","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001140361-20-025524","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036120025524/form4.xml","form_type":"4"}},{"id":2988085,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":81896,"kind":"person","name":"Hoffmann Bernhard","position":1,"cik":"0001830354","reported_name":"Hoffmann Bernhard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP of Corp. Dev. and Secretary"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-11-09T22:57:38.000Z","date":"2020-11-05","kind":"grant","acquired":true,"shares":4226,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. (\"Rexahn\") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. (\"Ocuphire\"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc. and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn.  Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1,373 shares vested on June 30, 2020, and the remaining shares vest in equal monthly installments from July 2020 through December 2021, subject to continued service."}],"balance_after":4226,"derivative":{"exercise_price":1.65,"expiration_date":"2020-06-30","underlying":"Common Stock","underlying_shares":4226},"source":{"system":"sec-edgar","filing":"0001596771-20-000110","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000159677120000110/primary_doc.xml","form_type":"4"}},{"id":2988084,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":81896,"kind":"person","name":"Hoffmann Bernhard","position":1,"cik":"0001830354","reported_name":"Hoffmann Bernhard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP of Corp. Dev. and Secretary"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-11-09T22:57:38.000Z","date":"2020-11-05","kind":"grant","acquired":true,"shares":30110,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. (\"Rexahn\") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. (\"Ocuphire\"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc. and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn.  Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"3,486 shares vested on December 31, 2019, and the remaining shares vest in equal monthly installments from January 2020 through December 2021, subject to continued service."}],"balance_after":30110,"derivative":{"exercise_price":1.21,"expiration_date":"2029-12-27","underlying":"Common Stock","underlying_shares":30110},"source":{"system":"sec-edgar","filing":"0001596771-20-000110","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000159677120000110/primary_doc.xml","form_type":"4"}},{"id":2988083,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":81896,"kind":"person","name":"Hoffmann Bernhard","position":1,"cik":"0001830354","reported_name":"Hoffmann Bernhard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP of Corp. Dev. and Secretary"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-11-09T22:57:38.000Z","date":"2020-11-05","kind":"grant","acquired":true,"shares":42867,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. (\"Rexahn\") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. (\"Ocuphire\"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc. and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn.  Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":42867,"derivative":{"exercise_price":0.9,"expiration_date":"2028-10-01","underlying":"Common Stock","underlying_shares":42867},"source":{"system":"sec-edgar","filing":"0001596771-20-000110","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000159677120000110/primary_doc.xml","form_type":"4"}},{"id":2988082,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":81896,"kind":"person","name":"Hoffmann Bernhard","position":1,"cik":"0001830354","reported_name":"Hoffmann Bernhard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP of Corp. Dev. and Secretary"}}],"security":"Common Stock","published_at":"2020-11-09T22:57:38.000Z","date":"2020-11-05","kind":"grant","acquired":true,"shares":100120,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. (\"Rexahn\") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. (\"Ocuphire\"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc. and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn.  Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc."}],"balance_after":100120,"source":{"system":"sec-edgar","filing":"0001596771-20-000110","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000159677120000110/primary_doc.xml","form_type":"4"}}]}